ArticleJACC. CardioOncology2021
Arterial Thromboembolism in Cancer Patients: A Danish Population-Based Cohort Study.
Article in JACC. CardioOncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 2 syntheses or guidelines pooled it, 72 citations in OpenAlex.
- Burden and distribution of venous thromboembolism across cancer types and stages: a meta-analysis of observational studies.Frontiers in oncology · 2025Pooled it
- Incidence of stroke in the first year after diagnosis of cancer-A systematic review and meta-analysis.Frontiers in neurology · 2022Pooled it
- Cancer-associated arterial thromboembolism: real-world burden from a nationwide electronic health record database.Journal of the National Cancer Institute · 2026Article
- Comparison of Direct Oral Anticoagulants and Low-Molecular-Weight Heparins in Cancer Patients with Nonvalvular Atrial Fibrillation: Insights from a Single-Center Experience.Anatolian journal of cardiology · 2026Article
- Association of a Cancer Diagnosis and Mortality After Ischemic and Hemorrhagic Stroke and Myocardial Infarction.Neurology · 2026Article
- Comparison of anticoagulants and risk of ischemic stroke in patients with acute cancer-associated venous thromboembolism.Blood advances · 2026Article
- Chemotherapy-associated coronary thrombosis presenting as acute coronary syndrome in breast cancer: a case report.BMC cardiovascular disorders · 2026Article
- Risk of Cardiovascular Disease Mortality in Patients With Diagnosed Cancer and Associated Genetic and Proteomic Mechanisms: A UK Biobank-Based Cohort Study.Journal of the American Heart Association · 2026Article
- Cancer-Associated Arterial Thrombosis: Mechanisms and Risk Factors.Oncology research · 2026Review
- Tissue factor activity and 1-year mortality in patients with active cancer and acute ischemic stroke: findings from the SCAN study.Research and practice in thrombosis and haemostasis · 2026Article
- Short and long-term outcomes of percutaneous coronary intervention in patients with active or prior history of cancer: a systematic review andInternational journal of cardiology. Heart & vasculature · 2025Article
- Development and validation of a risk assessment tool for ischemic stroke in cancer patients.Scientific reports · 2025Article
- Protruding Aortic Arch Thrombus in Cancer-Associated Stroke: Caution Regarding Endovascular Access.JACC. Case reports · 2025Article
- Arterial Thromboembolism Incidence in Japanese Patients With Lung Cancer.Cancer medicine · 2025Article
- Arterial and venous thromboembolic events in patients with cancer treated with targeted therapies: a population-based cohort study.EClinicalMedicine · 2025Article
- Thromboembolism in patients with melanoma receiving immune checkpoint inhibitors: incidence and risk factors.Immuno-oncology technology · 2025Article
- Risk of Cardiovascular Disease in Cancer Survivors after Systemic Treatment: A Population-Based Cohort Study.JACC. CardioOncology · 2025Article
- Clonal Hematopoiesis and Thrombosis.American journal of hematology · 2025Review
- Incidence and risk of arterial thromboembolism in cancer patients from a safety-net healthcare system.Journal of thrombosis and haemostasis : JTH · 2025Article
- Magnitude of cancer-associated thrombosis in Africa: A systematic review and meta-analysis.iScience · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe relation between cancer and arterial thromboembolism (ATE) remains unclear.
objectivesThe purpose of this study was to evaluate ATE risk in cancer patients.
methodsDanish registries were used to identify all cancer patients between 1997 and 2017, each matched to three cancer-free comparator individuals. ATE was defined as the composite of myocardial infarction, ischemic/unspecified stroke, and peripheral arterial occlusion. A competing risk approach was used to compute cumulative incidences and subdistribution hazard ratios (SHRs). Cause-specific hazard ratios (HRs) were calculated using Cox regression. Among cancer patients, mortality risk was estimated in Cox regression analysis by treating ATE as a time-varying exposure. Patients were followed for 12 months.
resultsThe study included 458,462 cancer patients and 1,375,386 comparator individuals. In the 6-month period following cancer diagnosis/index date, the cumulative incidence for ATE was 1.50% (95% confidence interval [CI]: 1.47% to 1.54%) in cancer patients and 0.76% (95% CI: 0.75% to 0.77%) in comparator individuals (HR: 2.36; 95% CI: 2.28 to 2.44). Among cancer patients age <65 years, 65 to 75 years, and >75 years, this was 0.79% (95% CI: 0.74% to 0.83%), 1.61% (95% CI: 1.55% to 1.67%), and 2.30% (95% CI: 2.22% to 2.38%), respectively. Other predictors for ATE among cancer patients were prior ATE (SHR: 2.96; 95% CI: 2.77 to 3.17), distant metastasis (adjusted SHR: 1.21; 95% CI: 1.12 to 1.30), and chemotherapy (SHR: 1.47; 95% CI: 1.33 to 1.61). Among cancer patients, ATE was associated with an increased risk of mortality (HR: 3.28; 95% CI: 3.18 to 3.38).
conclusionsCancer patients are at increased risk of ATE. Clinicians should be aware of this risk, which is associated with mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.